Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH

Essen 45239

5 studies enrolling now · 23 studies all time

What they study most

Adenocarcinoma, Bronchiectasis, Carcinoma, Non-Small-Cell Lung, Cystic Fibrosis, Familial Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases, Leukemia, Myeloid, Acute, Lung Diseases, Interstitial, Progressive Pulmonary Fibrosis, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases

Studies at this site

• The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis — Recruiting now
• A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast — Recruiting now
• A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis — Recruiting now
• A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases — Recruiting now
• A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment — Recruiting now
• FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression — Starting soon
• Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine — Running, not enrolling
• A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis — Completed
• A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™) — Completed
• A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis — Stopped early
• A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) — Completed
• A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) — Completed
• A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) — Completed
• Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) — Completed
• A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) — Completed
• Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis — Completed
• A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1 — Stopped early
• Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) — Completed
• Real World Data on Gi(l)Otrif® Dose Adjustment — Completed
• LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy — Completed
• Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment — Completed
• BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation — Completed
• Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF — Completed